Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (151-160 of 246) with videos related to

Pageof 25
Sort By:
RMD Open|January 8, 2026
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studiesPeter C Taylor, Arthur Kavanaugh, Louis Bessette, et al.
The Patient|June 28, 2018
The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic DiseasesTanja S Jørgensen, Marie Skougaard, Peter C Taylor, et al.
Annals of the Rheumatic Diseases|June 10, 2019
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept studySophie Glatt, Peter C Taylor, Iain B McInnes, et al.
Journal of Autoimmunity|July 3, 2025
STAT3 phosphorylation in the rheumatoid arthritis immunological synapseHila Novak-Kotzer, Jesusa Capera, Ashwin Jainarayanan, et al.
Rheumatology (Oxford, England)|August 25, 2023
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseasesPeter C Taylor, Ernest Choy, Xenofon Baraliakos, et al.
The Journal of Rheumatology|January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid ArthritisCharles Peterfy, Julie DiCarlo, Paul Emery, et al.
Rheumatology and Therapy|January 20, 2023
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical StudiesPeter C Taylor, Yun-Fei Chen, Janet Pope, et al.
Advances in Therapy|February 21, 2023
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsPeter C Taylor, Thomas Bieber, Rieke Alten, et al.
Rheumatology and Therapy|March 13, 2026
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS StudiesXenofon Baraliakos, Louis Bessette, Kurt de Vlam, et al.
Heart (British Cardiac Society)|November 18, 2016
Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritisFrancis O'Neill, Marietta Charakida, Eric Topham, et al.
Pageof 25

Showing results (151-160 of 246) with videos related to

Sort By:
Pageof 25
RMD Open|January 8, 2026
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studiesPeter C Taylor, Arthur Kavanaugh, Louis Bessette, et al.
The Patient|June 28, 2018
The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic DiseasesTanja S Jørgensen, Marie Skougaard, Peter C Taylor, et al.
Annals of the Rheumatic Diseases|June 10, 2019
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept studySophie Glatt, Peter C Taylor, Iain B McInnes, et al.
Journal of Autoimmunity|July 3, 2025
STAT3 phosphorylation in the rheumatoid arthritis immunological synapseHila Novak-Kotzer, Jesusa Capera, Ashwin Jainarayanan, et al.
Rheumatology (Oxford, England)|August 25, 2023
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseasesPeter C Taylor, Ernest Choy, Xenofon Baraliakos, et al.
The Journal of Rheumatology|January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid ArthritisCharles Peterfy, Julie DiCarlo, Paul Emery, et al.
Rheumatology and Therapy|January 20, 2023
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical StudiesPeter C Taylor, Yun-Fei Chen, Janet Pope, et al.
Advances in Therapy|February 21, 2023
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsPeter C Taylor, Thomas Bieber, Rieke Alten, et al.
Rheumatology and Therapy|March 13, 2026
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS StudiesXenofon Baraliakos, Louis Bessette, Kurt de Vlam, et al.
Heart (British Cardiac Society)|November 18, 2016
Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritisFrancis O'Neill, Marietta Charakida, Eric Topham, et al.
Pageof 25